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ABSTRACT 
Influenza is a world-wide infectious disease caused by influenza virus and 
results in much death annually. One of the key methods contributing to the 
prevention of this disease is influenza vaccines, which include live attenuated 
influenza vaccine(LAIV). Although the sequence of LAIV strain has been 
revealed more than 15 years, we still do not fully understand which part of 
LAIV mutated genes mainly contribute to the phenotype of attenuation.  
Based on prior researches, we tested the hypothesis that the amino 
acid(aa) residue position 83 and 86 of influenza A virus M2 cytoplasmic tail 
domain are responsible for virus replication. To study that, we generated 
panels of viruses with single amino acid mutations at target position based on 
A/Udorn/72 influenza A virus backbone. With verifying their sequences, 
plaques in MDCK cells and growth curves in both MDCK cells and primary 
human nasal epithelial cells are produced for identifying characteristics of 
different mutations. We conclude that specific mutations at position 83 and 
86 of M2 protein cytoplasmic tail domain can change the kinetics and amount 
of progeny virus produced in A/Udorn/72 influenza A virus replication.  
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Chapter 1: General Introduction 
Influenza  
Influenza as a disease in humans. Influenza viruses that cause 
significant disease in humans are classified into 3 types- A, B and C(3). Types 
A and B are the most significant human pathogens as they are the causal 
agents of seasonal influenza(4). Influenza C virus causes a mild infection. 
Influenza disease is characterized by varying severity of febrile and respiratory 
symptoms. While illness from seasonal strains generally lasts one to two 
weeks, influenza can cause hospitalization and death. The virus transmits 
through respiratory droplets and primarily infects epithelial cells of human 
respiratory tract(19). Populations at high risk of severe influenza disease 
burden including children younger than 5 years old(especially children 
younger than 2 years old), adults of 65 years old or elder, pregnant women, 
and Residents of nursing homes and other long-term care facilities(20). 
 Influenza as a disease in animals. Influenza is a disease common in a 
number animal species including horses, pigs, birds, wild aquatic mammals 
and domesticated animals. Type A virus is the important type as far as 
cross-species infections are concerned. It is distributed worldwide and usually 
causes a mild respiratory disease in animals. However, all species have their 
specific influenza A virus subtypes that circulate within them. The exception 
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is migratory waterfowl, which are hosts to all known subtypes of influenza A 
viruses.  
Birds, especially aquatic birds represent a vast reservoir of type A 
influenza viruses. These viruses have the capacity to spread to many 
mammals and sometimes cause high morbidity and mortality. Avian influenza 
is an extremely contagious and aggressive disease that causes rapid systemic 
illness and death in susceptible birds. Domestic chickens and turkeys are 
most severely affected; mortality in these birds often exceeds 50%. Estimates 
of global high pathogenic avian virus loss from the outbreaks since 2003 run 
into billions. Although all had serious consequences for the poultry industry, 
most remained geographically circumscribed. From the recent findings(52), it 
can be assumed that interspecies transmission of influenza A viruses occurs 
more frequently than we think, mainly from birds to mammalian species. 
Although the outbreaks in poultry have weakened economies and jeopardized 
food security, the greatest concern for human health is the risk that present 
conditions could give rise to an influenza pandemic(22). 
Both avian and swine influenza viruses have caused human pandemics. 
The transmission of avian influenza viruses or virus genes to humans is 
postulated to occur through pigs that act as the intermediate host. This 
involves either multiple mutational or gene segment reassortant events which 
generate viruses with recombinant genome segments that are highly 
pathogenic to human(21, 22, 23).  
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Public Health burden of influenza 
There are two major types of influenza diseases: seasonal influenza and 
pandemic influenza. Seasonal influenza diseases cause annual epidemics that 
peak during winter in temperate regions and circulate worldwide. It occurs 
globally with an annual attack rate estimated at 5-10% in adults and 20-30% 
in children, which result in about 3 to 5 million cases of severe illness and 
about 250000 to 500000 deaths. Vaccination is the most effective way to 
prevent influenza illness, but its effectiveness depends on how circulating 
viruses are well-matched with vaccine viruses. The circulating influenza 
viruses are constantly changing due to antigenic drift mechanism(26). 
Pandemic influenza diseases is an epidemic of an influenza virus that 
spreads on a worldwide scale and infects a large proportion of the human 
population. It can occur when a non-human(novel) influenza virus gains the 
ability for efficient and sustained human-to-human transmission and then 
spreads globally. There needs to be little pre-existing immunity in the human 
population for a pandemic to occur and this emergence of a new antigenic type 
of influenza into humans is called an “antigenic shift” mechanism. Pandemic 
influenza viruses cause more severe symptoms than seasonal ones, cause 
more total cases than seasonal influenza and have a larger impact on the 
general public, domestic and world economy. People have little or no 
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immunity to these viruses because they have no previous exposure to the 
virus, since pandemic viruses have proteins derived from swine or avian 
influenza segments.(29) There are 4 major flu pandemics recorded in human 
history, which happened in 1918-1919(“Spanish flu”, estimated 50 million 
people died), 1957-1958(69800 people died in US), 1968-1969(Hong Kong flu 
virus), and 2009-2010(H1N1 swine flu, 8870-18300 died)(27).  
Influenza disease is considered a worldwide public health problem 
according to huge disease burden. Escalating medical costs have increased 
the need to quantify the burden of influenza. Influenza is often under-reported, 
since the illness may be confused with other viral illnesses, which may cost 
more to detect. In addition to the direct costs of medical care, the indirect 
costs of influenza are substantial and stem largely from absenteeism and loss 
of work productivity. Estimates of the cost of influenza in the USA, France and 
Germany have shown that indirect costs can be 5- to 10-fold higher than 
direct costs. Other costs include impaired performance, which can reduce 
reaction times, and adverse effects on the quality of life of patients and their 
families. The main approach to the control of influenza and its associated 
costs is the administration of vaccines. Although vaccines are widely effective, 
the shortcomings of present vaccines, which include manufacturing 
limitations that prevent guaranteed adequate supply of vaccine, the difficulty 
in matching vaccines to circulating strains and the need for administration by 
injection, highlight the need for complementary treatment(24). The 
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economical burden of influenza is estimated to be 87 billion dollars per year in 
US(25). A pandemic could result in losses of between 0.5% and 4.3% in the 




Virus structure. Influenza viruses belong to the Orthomyxoviridae family of 
viruses. They are enveloped viruses with a segmented, negative sense RNA 
genome(Fig.1). The number of RNA segments compromising the viral genome 
varies, with influenza A and B viruses having 8 segments and influenza C 
virus having only 7 segments. The 8 segments of the influenza A virus genome 
are named after the major protein encoded by it - PB2, PB1, PA, NP, NS, HA, 
NA and M(6). These RNA segments encode for 11 viral proteins- two envelope 
glycoproteins HA and NA, three polymerase proteins PA, PB1 and PB2, two 
matrix proteins M1 and M2, three non-structural proteins NS1, NS2 ,PB1-F2 
and nucleoprotein NP(7). Among them, PB1, PB2, PA and NP combine viral 
RNA genes to build viral ribonucleoprotein complexes(vRNPs). Influenza A and 
B viruses are spherical or filamentous in shape, with spherical forms on the 
order of 100nm in diameter and the filamentous forms often in excess of 
300nm in length.   
 Influenza A virus infection and replication. The life cycle of influenza 
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virus starts with virus entry(Fig.2). HA protein on the surface of virus particles 
mediates the binding of the virus to the host cell sialic acid residues that have 
a 2,6 linkage to the adjacent galactose residue in humans or a 2,3 linkage in 
birds. Bound virus then enters the cell through 4 known mechanisms, called 
clathrin-mediated endocytosis(30), caveolae, macropinocytosis, and 
non-clathrin non-caveolae mechanism(31). 
The internalized virion is then in an endosome. The low pH environment of 
the endosome induces conformational changes in HA that expose a fusion 
peptide at the N-terminus of HA2. Then the fusion peptide inserts into the 
endosomal membrane, pulling the viral and endosomal membranes together 
for fusion. Simultaneously, the M2 protein selectively pumps protons from the 
endosome lumen into the virion interior, which disrupts the protein 
interactions between the vRNP complexes and M1 protein. Free vRNP 
complexes then travel through the fused membrane pore and go into the 
cytosol. 
Every viral RNA segment is bound by NP(nucleoprotein) and the 
polymerase proteins(PB1, PB2 and PA which form transcriptase complex). All 
of them form the viral riboncleoprotein(vRNP)(32). Influenza genome 
replication takes place in nucleus. The vRNP, however, is too large to enter the 
nucleus passively, so they enter in via binding to import in molecules that 
mediate transport through the nuclear pore complex. The dissociation of M1 
from vRNP exposes nuclear localization signals(NLS) on NP, which mediate 
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nuclear import(33). The PB2, PB1 and PA encode the RNA-dependent RNA 
polymerase(RdRp), which functions to produce both messenger RNA(mRNA) 
and genomic RNA. For genomic replication, virus RNA(vRNA) is first converted 
into positive-strand RNA by the RdRp. The RdRp also makes mRNA by using 5’ 
ends of host mRNAs that are cleaved by the RdRp from cellular 
pre-mRNAs(34). A 3’ poly A tail is added to the viral mRNA by polymerase 
stuttering(35). Unspliced and spliced mRNA transcripts leave the nucleus and 
are translated into proteins in the cytoplasm. All vRNPs that leave the nucleus 
are associated with M1 protein, which masks the NLS on the NP protein and 
exposes the nuclear export signals(NES) on the NS2/NEP protein. NS2/NEP 
mediates vRNP nuclear export. The unspliced and spliced vrial mRNAs are 
translated near the endoplasmic reticulum(ER) by host ribosomes, then 10 to 
11 viral proteins are produced. 
After translation, the membrane proteins HA, NA, M2 enter the ER where 
they fold and HA and NA are glycosylated(36). The proteins are then 
transported to the Golgi complex where HA and M2 are palmitoylated(37). The 
three proteins then reach the assembly site(lipid rafts) guided by apical sorting 
signals(38).   
With membrane proteins at the plasma membrane, 8 vRNP segments are 
packaged. The most prevailing model for vRNP packaging is the selective 
incorporation model. This model suggests that on the end of each vRNP 
segment, there are distinct packaging signals(39) which leads to the correct 
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packaging of 8 distinct RNA segments.  
Once the genome is completely enveloped, the viral membrane separates 
from the cellular membrane via membrane fission. The neuraminidase activity 
of NA cleaves the connection between HA protein and host cell sialic acid 
residues, leading to the release of complete influenza virion(40). Antiviral 
drugs Oseltamivir(41) and Zanamivir(42) are neuraminidase inhibitors. 
 Functions of the M2 protein. The M2 protein is one of the translation 
products of the influenza A virus M segment. It is an integral membrane 
protein 97 amino acids(aa) in length. M2 forms a tetramer and functions as an 
ion channel during virus entry. After the influenza A virus particle enters the 
cell through endocytosis, the M2 protein shuttles protons from the lumen of 
the endosome into the interior of virion. This changes the pH of the virion 
interior, leading to conformational changes in the M1 protein which disrupt 
the M1-vRNP association. vRNPs are subsequently released into the 
cytoplasm and can be imported into the nucleus of the cell to initiate RNA 
transcription and replication(2).  
M2 has three major domains: i) the extracellular domain(aa position 1-24), 
ii) the transmembrane domain(aa position 24-44), and iii) the cytoplasmic tail 
domain(aa position 44-97). In particular, the cytoplasmic tail of M2 has been 
associated with a number of critical functions including viral membrane 
scission and coordination of viral genome packaging. Truncations and amino 
acid substitutions in the M2 cytoplasmic tail have identified several regions 
  9 
that are critical for efficient production of influenza A virus particles. Amino 
acids at positions 82 to 89 of M2 protein are important for virus replication, 
but scanning alanine mutagenesis of this region failed to identify critical 
amino acids(15). Interestingly, positions 83 and 86 within this sequence are 
Ala and were not mutated in this study, suggesting that alanine residues at 
those positions may be important for M2 function.  
 Epithelial cells as a target for virus infection. The main targets of 
influenza virus in humans are the columnar epithelial cells of the human 
respiratory tract. In influenza infection, the receptor binding site of viral 
hemagglutinin(HA) is required for binding to galactose bound sialic acid on the 
surface of host cells(43). Cleavage of sialic acid is also essential for virus 
release from infected cells and is the functional role of viral 
neuraminidase(44). 
In this study, we used primary differentiated human nasal epithelial 
cell(hNEC) cultures isolated from healthy tissue of male and female 
donors(45,46,47) to study the replication of viruses. Nasal epithelial cells are 
the primary cell type infected with IAV and these cultures allowed us to 
investigate IAV infection and pathogenesis in a culture system derived from 
that tissue.  
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Influenza Vaccines   
The most effective means to control influenza virus infection is vaccination. 
Although there are various formulations, influenza vaccines currently have 
two main categories: inactivated influenza vaccine(IIV) and live attenuated 
influenza vaccines(LAIV)(11). The primary protection mediated by influenza 
vaccines is through antibodies that recognize the HA and NA proteins.  
Although there are some new ways to produce influenza vaccine, the most 
common way is using an egg-based manufacturing process, which has 
already existed for more than 70 years. Vaccine viruses are injected into 
fertilized hen’s eggs and incubated for several days to allow the viruses to 
replicate. The virus-containing fluid is harvested from the eggs. For IIV, the 
influenza viruses for the vaccine are then inactivated and virus antigen is 
partially purified. The manufacturing process continues with purification and 
testing. For the LAIV the viruses are weakened but not killed. The 
manufacturers then put doses into vials, syringes, or nasal sprayers for later 
testing and selling. This production method requires large numbers of chicken 
eggs to produce vaccine and usually takes the longest period of time to 
produce vaccine(49). 
There are several methods of influenza vaccination. For IIV, intramuscular 
and intradermal routes are the common ones, which deliver the vaccine 
through a needle and syringe direct into human body. For LAIV, however, it is 
used as nasal spray. The vaccine is sprayed into the patient’s nose for 
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inoculation through a specially designed tool(50). 
To assess the immunogenicity of a vaccine, the hemagglutination 
assay (HA) and the hemagglutination inhibition assay (HI) are available for 
quantitating the relative concentration of influenza virus and anti-viral 
antibodies. HA and HI apply the process of hemagglutination, in which sialic 
acid receptors on the surface of red blood cells (RBCs) bind to the 
hemagglutinin glycoprotein found on the surface of influenza virus and create 
a network structure with interconnected RBCs and virus particles(51). This 
structure maintains the RBCs in a suspension, viewed as a diffuse reddish 
solution. The formation of a pellet at the bottom of the tube depends on the 
concentrations of the virus and RBCs. When the relative virus concentration is 
too low, the RBCs are not constrained by the network and settle down to the 
bottom of the well. HI assay also adds anti-viral antibodies to interfere with 
the virus-RBC interaction.  
 Inactivated influenza vaccines. Inactivated influenza vaccine, also 
called “flu shot”, is the major type of influenza vaccine. It contains no live 
viruses but killed viruses or their subunits which can trigger the immune 
response of human body but would not cause flu disease. Since the virus is 
mutating all the time, each year a new influenza vaccine is made to protect 
against three or four viruses that are likely to cause disease in the upcoming 
flu season. Even when the selected strains in the vaccine do not perfectly 
match the circulating seasonal viruses, the vaccine can still provide some 
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protection(48). 
Live attenuated influenza vaccines. Current live attenuated influenza 
vaccines are based on a cold-adapted virus called A/Ann Arbor/6/1960(A/AA) 
type A master donor virus. This virus encodes the cold-adapted(ca), 
temperature-sensitive(ts), and attenuation(att) phenotypes. Besides the 
backbone of A/AA, LAIV strain also contains the two glycoprotein genes 
encoding HA and NA antigens from the virus strain that is the target of the 
vaccine – which could be any avian, animal or human influenza virus of 
pandemic potential or that is circulating in humans. The virus strains that 
serve as donors for the vaccine are selected by the WHO every year(12,13). 
The attenuation phenotype means viruses replicate less efficient and less 
virulent than their corresponding wild-type(WT)(2), and M segment of 
influenza A virus is verified to be responsible for at least part of this 
phenotype(14). 
 Antigenic drift and shift. Influenza A viruses are characterized by the 
hemagglutinin(HA or H) and neuraminidase(NA or N) encoded by the virus. 
These two proteins are classified into serotypes and subtypes. Influenza A 
virus has 16 types of HA and 9 types of NA. This characteristic contributes to 
the mutation mechanisms of influenza A virus, which are named antigenic 
drift and antigenic shift. These two mechanisms are believed to explain why 
the influenza A virus can cause epidemics annually and pandemics at 
frequent intervals(1). 
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Antigenic drift is responsible for annual influenza epidemics. Circulating 
influenza A viruses are constantly mutating. Minor antigenic mutations from 
random mutational events to HA and NA help the virus evade the existing 
immune response of individuals generated from previous influenza A virus 
exposure(9).  
Antigenic shift, although less frequent, causes much more serious 
consequences(9). Since Influenza A virus not only infects humans, but also 
infects other animals like birds and swines, , the bird influenza A virus strains 
can sometimes jump from aquatic birds to humans. If the cell is infected by 
both human influenza A strain and bird influenza A virus strain, genes from 
two strains mix together to yield a new strain(10). This major change of 
antigenic type of HA or NA, named antigenic shift, is responsible for influenza 
pandemics, which leads to widespread infection, societal disruption and 
global mortality measured in the millions(9).  
 
We sought to test the hypothesis that influenza A virus M2 protein 83 and 
86 position amino acids are important for virus attenuation. The result of this 
study would provide us genome target of attenuating influenza A virus, which 
could contribute to designing novel live attenuated influenza vaccine.  
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Figure. 1. Structure of Influenza A Virus(Flint, S. J. et al. Principles of Virology) 
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Figure. 2. Life Cycle of Influenza A Virus(Das, Kalyan, et al. "Structures of 
influenza A proteins and insights into antiviral drug targets." Nature structural & 
molecular biology 17.5(2010): 530-538.) 




Figure. 3. Amino Acid Frequency of amino acids at positions 82-87 of the 
Influenza A virus M2 protein cytoplasmic tail. The relative size of the amino acid 
abbreviations at each position represents their relative frequencies in human 
influenza A virus M2 sequences present in Influenza Research Database. The 
asterisk(*) indicates position 86 which is encoded by S in live attenuated influenza 
virus(LAIV) vaccine. It has less than 0.1% relative frequency and is therefore not 
visible in this representation.  
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Chapter 2: Characterization of M2-A86 mutated 
viruses 
BACKGROUND: 
The M2 protein is one of the translation products of the M segment of 
Influenza A virus. It acts as an ion channel to shuttle hydrogen ions from the 
lumen of endosome into the interior of the virion during virus entry into cells. 
This disrupts the interactions between viral proteins and allows for the 
dissociation of the viral ribonucleoprotein(vRNP) complexes from the site of 
virus-endosome membrane fusion so the vRNPs can be transported to the cell 
nucleus to initiate viral gene expression. 
The wild-type M2 protein gene sequence has 97 amino acids, and amino 
acids 44 to 97 are considered to be the cytoplasmic tail domain. Panels of M2 
proteins encoding mutations of these amino acids have been generated and 
tested for their effects on virus replication. Truncating the M2 cytoplasmic tail 
at position 82 but not after position 90 reduced infectious virus production, 
suggesting a region between amino acids 82 and 90 was critical for infectious 
virus production. Alanine-scanning mutagenesis across this region did not, 
however, identify critical amino acids mediating this attenuation.  
In previous analysis, the two alanines at positions 83 and 86 were not 
mutated so we hypothesize that these two residues may be critical for 
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supporting influenza A virus replication. The relative frequencies of amino 
acid in position 86 in all human influenza A virus show that about 2/3 of 
viruses have alanine at this position, while around 1/3 have valine(54). 
However, for LAIV virus strains, serine appears at this position. This is also 
the only different amino acid in the M2 protein between wild type influenza A 
virus A/Ann Arbor/6/60 strain and the LAIV strain derived from it [57]. The 
Chou & Fasman algorithm, which predicts secondary structure, indicates that 
region 82-90 of the M2 cytoplasmic tail forms a structure dominated by 
alpha-helixes. When alanine is changed to serine, the secondary structure of 
protein would change and disrupt the continuous alpha-helix domain(Fig.4), 
while alanine scanning would not do that [55,56].  
In this study, we hypothesize that amino acid position 86 of influenza A 
virus M2 protein is important for virus replication. Recombinant viruses 
encoding M2 proteins with mutations at position 86 were rescued and 
characterized for their replication in MDCK cells and hNEC cultures. These 
results suggest additional amino acids may be contributing to the attenuation 
of LAIV.  
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MATERIALS AND METHODS 
Plasmids. The plasmid pHH21 M-Udorn encodes the influenza 
A/Udorn/72 virus M segment under the control of the human RNA 
polymerase I promotor and murine RNA polymerase I terminator(53, 58). The 
pHH21 M-Udorn plasmid was altered using Quikchange Site-Directed 
Mutagenesis(Stratagene) protocol to introduce required A86 series mutations. 
The sequence of the forward and reverse mutagenesis primers used to 
introduce all mutations is given in Table 1. The PCR products were digested 
using Dpn1 enzyme to remove parental supercoiled DNA and then 
transformed into competent bacterial(DH5α) cells. DNA from several bacterial 
clones was extracted using QIAprep Spin Miniprep Kit(Qiagen). The DNA was 
sequenced for the appropriate mutations by sequencing the with M 
segment-specific primers(named FluA1 and FluA2 - given in Table 1). This 
sequencing was done at the Synthesis & Sequencing Facility of the Johns 
Hopkins University(Baltimore, MD) using Applied Biosystems 3730xl DNA 
Analyzer and dye terminator sequencing technology. The concentration of 
plasmid DNA was determined using the NanoDrop spectrophotometer 
ND-1000(Thermo Fisher Scientific). 
Cell lines. Madin Darby canine kidney(MDCK) cells were maintained in 
DMEM with 10% fetal bovine serum(FBS), 100U/ml Penicillin, 100μg/ml 
Streptomycin and 2mM L-Glutamine at 37°C with 5% CO2 and were passaged 
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1:10 every 3 days.  
293Ts were maintained in DMEM with 10% FBS, 100U/ml Penicillin, 
100μg/ml Streptomycin and 2mM L-Glutamine at 37°C with 5% CO2 and were 
passaged 1:10 every 3 days. 6-well plates coated with poly-L-lysine were 
seeded with approximately 1.2*10^6 cells per well 18-24 hours prior to 
transfection to target 60-70% confluence at the time of transfection. 
Human nasal epithelial cell cultures. Human nasal epithelial 
cells(hNEC) were collected from non-diseased nasal mucosa of patients 
undergoing endoscopic sinonasal surgery for non-sinusitis indications, 
including dacryocystorhinostomy, approach to anterior skull base pathology, 
or removal of benign nasal masses.(Fischer et al) The cells were collected from 
2 male and 2 female donors. The cells were differentiated at an air-liquid 
interface(ALI) in 24-well Falcon filter inserts(0.4-μM pore; 0.33cm2; Becton 
Dickinson) before infection, using ALI medium as basolateral medium. 
Recombinant viruses. The 12 plasmid based recombinant virus rescue 
system(58, 60) was used to generate all the mutated viruses. 293T cells were 
transfected with 0.5μg of pHH21 plasmids encoding A/Udorn/72 PB1, PB2, 
PA, HA, NA, NP, NS and M; and plasmids(under the control of cellular RNA 
polymerase II promoters) encoding A/Udorn/72 PB1, PB2, NP(1μg each) and 
PA(0.2μg). Transfection reagent TransIT-LT-1(LT1)(Mirus, Madison, WI) was 
mixed with OptiMEM medium(Gibco, Carlsbad, CA) and incubated at room 
temperature for 15minutes at a ratio of 2μl LT1 to 1μg plasmid DNA. The 
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plasmids were mixed(each transfection well with appropriate M segment) with 
indicated quantities and incubated with LT1-OptiMEM mixture for another 15 
minutes. Medium was removed from 293T cells in 6-well plates and replaced 
with 2ml of OptiMEM. The corresponding transfection solution was added to 
each well. The plates were incubated at 32°C with 5% CO2. After 24 hours, 
N-acetyl trypsin(NAT)(Sigma, St.Louis, MO) was added to a final concentration 
of 10μg/ml to each well.. After incubation for 4 hours at 32°C with 5% CO2, 
approximately 5^105 MDCK cells in 100μl OptiMEM were added to each well 
of 293T cells. The plates were incubated at 37°C with 5% CO2. 1ml of 
transfected cell supernatant were collected and replaced with 1ml DMEM with 
4μg/ml NAT, 100U/ml Penicillin 100μg/ml Streptomycin, 2mM L-Glutamine 
and 0.5% bovine serum albumin(BSA)(Sigma)(Infectious medium with NAT, 
IM+NAT) daily until obvious signs of cytopathic effect were visible.  
The recombinant viruses used in this study were all generated in the 
A/Udorn/72(rUdorn) genetic background(60). The viruses with mutations at 
position 86 are listed in Table 2 and include mutation to amino acids V, S, M, 
E and K.  
TCID50 assay Fifty percent tissue culture infectious dose(TCID50) was 
determined in 96-well plates of MDCK cells using a ten-fold dilution series of 
each virus sample in IM+NAT. 120μl of each dilution was added to each of 6 
wells and the plates were incubated at 32°C with 5% CO2 for 7 days. The cells 
were then fixed with 4% formaldehyde at least 1 hour and stained with 
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napthol blue black for at least 4 hours. The cytopathic effect was scored 
visually and the TCID50 value for the virus sample was obtained using the 
Reed and Muench calculation. 
Plaque assay and plaque picking. Plaque assays were done to purify 
virus clones from transfected cell-supernatants and to quantify the plaque 
morphology of virus strains. 6-well plates were seeded with MDCK cells and 
allowed to reach 90-100% confluence. 100μl of transfected-cell supernatant 
or virus-infected cell supernatant was serially diluted ten-fold with IM+NAT. 
Virus dilutions were added to each well and incubated at room temperature 
for one hour with rocking gently. Then the wells were covered with 2% agarose 
mixed with 2XMEM with 4μg/ml NAT. Plates were incubated at 32°C with 5% 
CO2 for 72-96 hours. Plaques were picked using a 1ml pipette, then placed in 
tubes containing IM and stored at -70°C . The plates were fixed with 4% 
formaldehyde in PBS for 1 hour and stained with napthol blue black for at 
least 4 hours to reveal the plaques.  
To quantify plaque area, images of the plaques were taken using a 
dissecting microscope with a Olympus DP-70 color camera and including a 
standard ruler in the image. Photos opened by software ImageJ were turned 
into 8-bit images photo background was subtracted with “Rolling ball radius 
50.0 pixels” and ticking “Light background” and “Sliding paraboloid” items. 
Image threshold was adjusted to make the plaques easy to recognize. Using 
“Paintbrush tool”, the plaque borders were highlighted manually, then filled to 
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create a black and white image. Plaque area data from ImageJ with Prism 6.  
Virus infection for generating virus stocks Virus infections were done 
using MDCK cells that were approximately 100% confluent in T150(150cm2) 
flasks. 100μl of purified virus(plaque picking products) was added to 5ml of 
IM+NAT and this was incubated in the T150 flasks for 1hour at room 
temperature with gently rocking. 15ml more IM+NAT was added and flasks 
were incubated at 32 ° C. The cells were monitored daily for cytopathic 
effect(CPE) and the supernatants were harvested when approximately 40-50% 
of cells had detached from the flask bottom surface. The harvested samples 
are seed stocks. The seed stocks were sequenced for specific mutations and 
infectious virus titrated by TCID50 assay. When the seed stock sequence was 
verified, working stocks(at MOI=0.001) were generated from seed stocks in the 
same way as above. The working stocks were also titrated by TCID50, 
sequenced and used in all experiments. 
Low MOI growth curves(GCs). To determine virus replication kinetics, 
different panels of mutated A86 series viruses were used in 24-well plates with 
near 100% confluence MDCK cells or fully differentiated hNECs. Viruses were 
diluted to a low multiplicity of infection(MOI) of 0.001 infectious virus particles 
per cell in IM+NAT(MDCK) or IM(hNEC). The virus inoculum was then added 
to wells and incubated for 1 hour with rocking at room temperature(MDCK 
GCs) or under 32°C or 37°C with 5% CO2 for 1 hour(hNEC GCs). For MDCK 
infections, the inoculum was then aspirated and replaced with 500μl IM+NAT, 
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and samples were taken at 1, 12, 24, 36, 48, and later every 24hours and 
replaced with fresh 500μl IM+NAT. For hNEC infections, The inoculum was 
then aspirated and at indicated times post infection(1, 12, 24, 36, 48, 72, 96, 
120, 144 hours post infection, hpi), 100μl IM was added to each well, the 
plates incubated at 32°C or 37°C with 5% CO2 for 10 minutes, and the 
supernatant harvested. The basolateral medium was replaced every 48 hours.   
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Figure. 4. Predicted secondary structure of amino acids 82-89 of the M2 protein of 
A/Udorn/72 and the effect of amino acid substitutions at position 86.
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Plasmid Forward Primer Reverse Primer 
pHH21 Ud-M2-A86V 5’ CAA AAT GAC TGT CGT 
CAA CAT CCA CAG C 3’ 
5’ GAA CAG CAG AGT GCT 
GTG GAT GTT GAC G 3’ 
pHH21 Ud-M2A86S 5’ CAA AAT GAC TGT CGT 
CAG AAT CCA CAG C 3’ 
5’ GAA CAG CAG AAT GCT 
GTG GAT TCT GAC G 3’ 
pHH21 Ud-M2A86M 5’ CAA AAT GAC TGT CGT 
CCA TAT CCA CAG C 3’ 
5’ GAA CAG CAG AGT GCT 
GTG GAT ATG GAC G 3’ 
pHH21 Ud-M2A86E 5’ CAA AAT GAC TGT CGT 
CTT CAT CCA CAG CA 3’ 
5’ GAA CAG CAG AGT GCT 
GTG GAT GAA GAC G 3’ 
pHH21 Ud-M2A86K 5’ CAA AAT GAC TGT CGT 
CCT TAT CCA CAG CA 3’ 
5’ GAA CAG CAG AGT GCT 
GTG GAT AAG GAC G 3’ 
pHH21 Ud-M2A83V 5' GAA CAG CAG AGT GTT 
GTG GAT GCT GAC G 3' 
5' C GTC AGC ATC CAC 
AAC ACT CTG CTG TTC 3' 
pHH21 Ud-M2A83P 5' GAA CAG CAG AGT CCT 
GTG GAT GCT GAC G 3' 
5' C GTC AGC ATC CAC 
AGG ACT CTG CTG TTC 3' 
pHH21 Ud-M2A83M 5' GAA CAG CAG AGT ATG 
GTG GAT GCT GAC G 3' 
5' C GTC AGC ATC CAC 
CAT ACT CTG CTG TTC 3' 
pHH21 Ud-M2A83E 5' GAA CAG CAG AGT GAA 
GTG GAT GCT GAC G 3' 
5' C GTC AGC ATC CAC 
TTC ACT CTG CTG TTC 3' 
pHH21 Ud-M2A83K 5' GAA CAG CAG AGT AAG 
GTG GAT GCT GAC G 3' 
5' C GTC AGC ATC CAC 
CTT ACT CTG CTG TTC 3' 
pHH21 Ud-M FluA1 
5’ ATA CGT CTC GTA TTA 
GTA GAA ACA AGG TAG 3’ 
FluA2 
5’ CGA CGT CTC CGG GAG 
CAA AAG CAG GTA G 3’ 
Table 1. Primer sequences used in project 
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Mutation Amino Acid(AA) % Relative Freq Residue Properties AA structure 
WT Alanine 65 Small Hydrophobic 
 
A86V Valine 34 Small Hydrophobic 
 
A86S Serine* 0.01 Small Nucleophilic 
 
A86M Methionine 0 Large Hydrophobic 
 
A86E Glutamic Acid 0 Acidic 
 
A86K Lysine 0 Basic 
 
Table 2. The viruses designed with mutations at position 86  
*A86S is the LAIV strain mutation 
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RESULTS 
Rescue of recombinant influenza viruses encoding M2-A86 mutations. 
Recombinant viruses expressing the panel of M2-A86 mutations shown in 
Table 2 were successfully rescued. The entire coding region of the M-segment 
from each virus was sequenced to confirm the presence of the desired 
mutation and to verify that no other amino acid changes were present.  
Plaque assay of A/Udorn/72 viruses containing M2-A86 mutations. As 
a first measure to determine if mutations at M2-A86 could alter influenza A 
virus replication, we determined the plaque morphology and size on MDCK 
cells. All of the viruses are able to form discernible plaques(Fig. 5A).The area of 
individual plaques was then calculated and viruses containing the M2-A86S 
mutations generated slightly smaller plaques compared to WT viruses. This 
result indicates that the serine mutation, which is only present in the LAIV 
virus strain, negatively impacts influenza A virus plaque formation, though 
the effect is rather small.    
Replication of recombinant viruses encoding M2-A86 mutations at 
32°C. To further characterize the replication of recombinant influenza A 
viruses encoding M2-A86 mutations, a multiple-step growth curve was 
performed on MDCK and differentiated human nasal epithelial cell(hNEC) 
cultures. To mimic the natural infection temperature of the upper respiratory 
tract, the growth curves were performed at 32°C. All the recombinant viruses 
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reached peak virus titers at 72 hpi, but viruses encoding M2-A86V, A86M and 
A86K replicated with slightly faster similar kinetics at early times post 
infection in MDCK cells(Fig.6A).  
In hNEC cultures, recombinant viruses encoding M2-A86S, A86E and 
A86K showed reduced kinetics of virus production and reached peak virus 
titer 24 hours later than the other recombinant viruses(Fig.7A). The difference 
between WT and M2-A86S or M2-A86E was approximately 10 fold at multiple 
timepoints, while the recombinant virus encoding M2 A86K showed reduced 
virus titers at only one time post infections, suggesting a smaller effect of this 
mutation on virus replication in hNEC cultures.   
These data demonstrates that at 32°C in MDCK cells, M2-A86 mutations 
do not adversely affect virus replication and some mutations may in fact 
increase virus replication slightly. However, in a physiologically relevant cell 
culture system like hNEC cultures, the M2-A86S and M2-A86E mutations 
consistently reduce virus replication. To further characterize virus replication, 
we chose a subset of recombinant viruses – M2-A86V, S and E – to represent 
viruses that have slightly enhanced replication in MDCK cells or reduced 
replication in hNEC cultures(Fig.6B & Fig.7B). 
Replication of recombinant viruses encoding M2-A86 mutations at 
37°C. While the upper respiratory tract temperature is approximately 32°C, 
core human body temperature and therefore the temperature of the lower 
respiratory tract, is 37°C. The M2-A86S mutation attenuated influenza virus 
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replication in hNEC cultures but not in MDCK cells, a phenotype that is 
consistent with that observed with LAIV replication in those same cell culture 
systems(Fisher, et al 2015). To determine if the virus replication patterns of 
the M2-A86V, S and E viruses were affected by increased temperature, 
multi-step virus growth curves were performed at 37°C using both MDCK 
and hNEC cultures. At 37°C, all four viruses replicated with identical 
kinetics and to similar peak titers, indicating that the slightly enhanced 
replication of the virus encoding M2-A86V was not present at higher 
temperature(Fig.8). In hNECs, all three M2 mutations resulted in reduced 
virus replication kinetics and peak titer(Fig.9). Recombinant viruses encoding 
M2-A86S and M2-A86E had peak titers approximately 100-fold lower than WT 
virus, which are much larger than the difference less than 10-fold under 32°
C. M2-A86V virus replicates better than M2-A86S and M2-A86E, but still 
averagely 10-fold lower than WT virus.  
Taken together, this data demonstrate that the M2-A86S and M2-A86E 
mutations can attenuate A/Udorn/72 virus replication by reducing infectious 
virus production in hNEC cultures but not in MDCK cells. This attenuation is 
even greater at higher temperatures.   






Figure. 5. Effect of amino acid substitutions at position 86 of the M2 protein on 
influenza A virus plaque morphology in MDCK cells.(A) Plaque morphology of 
recombinant influenza A viruses encoding mutations at position 86 of the M2 
protein.(B) Plaque area was calculated and mean(cross), median(line), 50% 
percentiles(box) and range(whiskers) are shown. Significant differences were 
determined by student t-test: ** P≤0.01. At least 60 plaques were quantified for 
each virus.  








Figure. 6.  Effect of amino acid substitutions at position 86 of the M2 protein on 
influenza A virus replication in MDCK cells at 32°C(A) A multi-step growth curve 
was performed on MDCK cells with the indicated recombinant viruses. In(B), 
representative viruses from(A) are shown. Statistical differences determined by 
MANOVA followed by Bonferroni post test: **=P<0.01; ***=P<0.001. L.O.D=limit of 
detection=2.37. 







Figure. 7. Effect of amino acid substitutions at position 86 of the M2 protein on 
influenza A virus replication in hNEC cultures at 32°C.(A) A multistep growth 
curve was performed on hNEC cultures with the indicated recombinant viruses. 
In(B), representative viruses from(A) are shown. Statistical differences determined 
by MANOVA followed by Bonferroni post test: *=P<0.05; **=P<0.01; ****=P<0.0001. 
L.O.D=limit of detection=2.37.  
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Figure. 8. Effect of amino acid substitutions A86V, A86S and A86E of the M2 
protein on influenza A virus replication in MDCK cells at 37°C. A multistep growth 
curve was performed on MDCK cells with the indicated recombinant viruses. 
Statistical differences determined by MANOVA followed by Bonferroni post test. 
L.O.D=limit of detection=2.37.  




Figure. 9.Effect of amino acid substitutions A86V, A86S and A86E of the M2 
protein on influenza A virus replication in hNEC cultures at 37°C.. A multistep 
growth curve was performed on hNEC cultures with the indicated recombinant 
viruses. Statistical differences determined by MANOVA followed by Bonferroni 
post test: **=P<0.01; ***=P<0.001. L.O.D=limit of detection=2.37.  
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Chapter 3: Characterization of M2-A83 mutated 
viruses 
BACKGROUND 
The M2 protein is one of the translation products of the M segment of 
Influenza A virus. It acts as an ion channel to shuttle hydrogen ions from the 
lumen of endosome into the interior of the virion during virus entry into cells. 
This disrupts the interactions between viral proteins and allows for the 
dissociation of the viral ribonucleoprotein(vRNP) complexes from the site of 
virus-endosome membrane fusion so the vRNPs can be transported to the cell 
nucleus to initiate viral gene expression. 
The wild-type M2 protein gene sequence has 97 amino acids, and amino 
acids 44 to 97 are considered to be the cytoplasmic tail domain. Panels of M2 
proteins encoding mutations of these amino acids have been generated and 
tested for their effects on virus replication. Truncating the M2 cytoplasmic tail 
at position 82 but not after position 90 reduced infectious virus production, 
suggesting a region between amino acids 82 and 90 was critical for infectious 
virus production. Alanine-scanning mutagenesis across this region did not, 
however, identify critical amino acids mediating this attenuation.  
In previous analysis, the two alanines at positions 83 and 86 were not 
mutated so we hypothesize that these two residues may be critical for 
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supporting influenza A virus replication. The relative frequencies of amino 
acid in position 83 in all human influenza A virus show that more than 99% of 
viruses have Alanine at this 83 position(54). The Chou & Fasman algorithm, 
which predicts secondary structure, indicates that region 82-90 of the M2 
cytoplasmic tail forms a structure dominated by alpha-helixes. When alanine 
is changed to proline, the secondary structure of protein would change and 
disrupt the continuous alpha-helix domain(Fig.10), while alanine scanning 
would not do that [55,56].  
In this study, we hypothesize that amino acid position 83 of influenza A 
virus M2 protein is important for virus replication. Recombinant viruses 
encoding M2 proteins with mutations at position 83 were rescued and 
characterized for their replication in MDCK cells and hNEC cultures. These 
results suggest additional amino acids may be contributing to the attenuation 
of LAIV.  
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MATERIALS AND METHODS 
Plasmids. The plasmid pHH21 M-Udorn encodes the influenza 
A/Udorn/72 virus M segment under the control of the human RNA 
polymerase I promotor and murine RNA polymerase I terminator(53, 58). The 
pHH21 M-Udorn plasmid was altered using Quikchange Site-Directed 
Mutagenesis(Stratagene) protocol to introduce required A83 series mutations. 
The sequence of the forward and reverse mutagenesis primers used to 
introduce all mutations is given in Table 1. The PCR products were digested 
using Dpn1 enzyme to remove parental supercoiled DNA and then 
transformed into competent bacterial(DH5α) cells. DNA from several bacterial 
clones was extracted using QIAprep Spin Miniprep Kit(Qiagen). The DNA was 
sequenced for the appropriate mutations by sequencing the with M 
segment-specific primers(named FluA1 and FluA2 - given in Table 1). This 
sequencing was done at the Synthesis & Sequencing Facility of the Johns 
Hopkins University(Baltimore, MD) using Applied Biosystems 3730xl DNA 
Analyzer and dye terminator sequencing technology. The concentration of 
plasmid DNA was determined using the NanoDrop spectrophotometer 
ND-1000(Thermo Fisher Scientific). 
Cell lines. Madin Darby canine kidney(MDCK) cells were maintained in 
DMEM with 10% fetal bovine serum(FBS), 100U/ml Penicillin, 100μg/ml 
Streptomycin and 2mM L-Glutamine at 37°C with 5% CO2 and were passaged 
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1:10 every 3 days.  
293Ts were maintained in DMEM with 10% FBS, 100U/ml Penicillin, 
100μg/ml Streptomycin and 2mM L-Glutamine at 37°C with 5% CO2 and were 
passaged 1:10 every 3 days. 6-well plates coated with poly-L-lysine were 
seeded with approximately 1.2*10^6 cells per well 18-24 hours prior to 
transfection to target 60-70% confluence at the time of transfection. 
Human nasal epithelial cell cultures. Human nasal epithelial 
cells(hNEC) were collected from non-diseased nasal mucosa of patients 
undergoing endoscopic sinonasal surgery for non-sinusitis indications, 
including dacryocystorhinostomy, approach to anterior skull abse pathology, 
or removal of benign nasal masses.(Fischer et al) The cells were collected from 
1 male and 1 female donors. The cells were differentiated at an air-liquid 
interface(ALI) in 24-well Falcon filter inserts(0.4-μM pore; 0.33cm2; Becton 
Dickinson) before infection, using ALI medium as basolateral medium. 
Recombinant viruses. The 12 plasmid based recombinant virus rescue 
system(58, 60) was used to generate all the mutated viruses. 293T cells were 
transfected with 0.5μg of pHH21 plasmids encoding A/Udorn/72 PB1, PB2, 
PA, HA, NA, NP, NS and M; and plasmids(under the control of cellular RNA 
polymerase II promoters) encoding A/Udorn/72 PB1, PB2, NP(1μg each) and 
PA(0.2μg). Transfection reagent TransIT-LT-1(LT1)(Mirus, Madison, WI) was 
mixed with OptiMEM medium(Gibco, Carlsbad, CA) and incubated at room 
temperature for 15minutes at a ratio of 2μl LT1 to 1μg plasmid DNA. The 
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plasmids were mixed(each transfection well with appropriate M segment) with 
indicated quantities and incubated with LT1-OptiMEM mixture for another 15 
minutes. Medium was removed from 293T cells in 6-well plates and replaced 
with 2ml of OptiMEM. The corresponding transfection solution was added to 
each well. The plates were incubated at 32°C with 5% CO2. After 24 hours, 
N-acetyl trypsin(NAT)(Sigma, St.Louis, MO) was added to a final concentration 
of 10μg/ml to each well. After incubation for 4 hours at 32°C with 5% CO2, 
approximately 5^105 MDCK cells in 100μl OptiMEM were added to each well 
of 293T cells. The plates were incubated at 37°C with 5% CO2. 1ml of 
transfected-cell supernatant were collected and replaced with 1ml DMEM with 
4μg/ml NAT, 100U/ml Penicillin 100μg/ml Streptomycin, 2mM L-Glutamine 
and 0.5% bovine serum albumin(BSA)(Sigma)(Infectious medium with NAT, 
IM+NAT) daily until obvious signs of cytopathic effect were visible.  
The recombinant viruses used in this study were all generated in the 
A/Udorn/72(rUdorn) genetic background(60). The viruses with mutations at 
position 83 are listed in Table 3 and include mutation to amino acids V, P, M, 
E and K.  
TCID50 assay Fifty percent tissue culture infectious dose(TCID50) was 
determined in 96-well plates of MDCK cells using a ten-fold dilution series of 
each virus sample in IM+NAT. 120μl of each dilution was added to each of 6 
wells and the plates were incubated at 32°C with 5% CO2 for 7 days. The cells 
were then fixed with 4% formaldehyde at least 1 hour and stained with 
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napthol blue black for at least 4 hours. The cytopathic effect was scored 
visually and the TCID50 value for the virus sample was obtained using the 
Reed and Muench calculation. 
Plaque assay and plaque picking. Plaque assays were done to purify 
virus clones from transfected cell-supernatants and to quantify the plaque 
morphology of virus strains. 6-well plates were seeded with MDCK cells and 
allowed to reach 90-100% confluence. 100μl of transfected-cell supernatant 
or virus-infected cell supernatant was serially diluted ten-fold with IM+NAT. 
Virus dilutions were added to each well and incubated at room temperature 
for one hour with rocking gently. Then the wells were covered with 2% agarose 
mixed with 2XMEM with 4μg/ml NAT. Plates were incubated at 32°C with 5% 
CO2 for 72-96 hours. Plaques were picked using a 1ml pipette, then placed in 
tubes containing IM and stored at -70°C. The plates were fixed with 4% 
formaldehyde in PBS for 1 hour and stained with napthol blue black for at 
least 4 hours to reveal the plaques.  
To quantify plaque area, images of the plaques were taken using a 
dissecting microscope with a Olympus DP-70 color camera and including a 
standard ruler in the image. Photos opened by software ImageJ were turned 
into 8-bit images photo background was subtracted with “Rolling ball radius 
50.0 pixels” and ticking “Light background” and “Sliding paraboloid” items. 
Image threshold was adjusted to make the plaques easy to recognize. Using 
“Paintbrush tool”, the plaque borders were highlighted manually, then filled to 
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create a black and white image. Plaque area data from ImageJ was analyzed 
with Prism 6.  
Virus infection for generating virus stocks Virus infections were done 
using MDCK cells that were approximately 100% confluent in T150(150cm2) 
flasks. 100μl of purified virus(plaque picking products) was added to 5ml of 
IM+NAT and this was incubated in the T150 flasks for 1hour at room 
temperature with gently rocking. 15ml more IM+NAT was added and flasks 
were incubated at 32 ° C. The cells were monitored daily for cytopathic 
effect(CPE) and the supernatants were harvested when approximately 40-50% 
of cells had detached from the flask bottom surface. The harvested samples 
are seed stocks. The seed stocks were sequenced for specific mutations and 
infectious virus titrated by TCID50 assay. When the seed stock sequence was 
verified, working stocks(at MOI=0.001) were generated from seed stocks in the 
same way as above. The working stocks were also titrated by TCID50, 
sequenced and used in all experiments. 
Low MOI growth curves(GCs). To determine virus replication kinetics, 
different panels of mutated A83 series viruses were used in 24-well plates with 
near 100% confluence MDCK cells or fully differentiated hNECs. Viruses were 
diluted to a low multiplicity of infection(MOI) of 0.001 infectious virus particles 
per cell in IM+NAT(MDCK) or IM(hNEC). The virus inoculum was then added 
to wells and incubated for 1 hour with rocking at room temperature(MDCK 
GCs) or under 32°C with 5% CO2 for 1 hour(hNEC GCs). For MDCK infections, 
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the inoculum was then aspirated and replaced with 500μl IM+NAT, and 
samples were taken at 1, 12, 24, 36, 48, and later every 24hours and replaced 
with fresh 500μl IM+NAT. For hNEC infections, The inoculum was then 
aspirated and at indicated times post infection(1, 12, 24, 36, 48, 72, 96, 120, 
144 hours post infection, hpi), 100μl IM was added to each well, the plates 
incubated at 32 ° C with 5% CO2 for 10 minutes, and the supernatant 
harvested. The basolateral medium was replaced every 48 hours.   
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Figure. 10.  Predicted secondary structure of amino acids 82-89 of the M2 protein 
of A/Udorn/72 and the effect of amino acid substitutions at position 83. 
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Mutation Amino Acid(AA) % Relative Freq Residue Properties AA structure 
WT Alanine 99 Small Hydrophobic 
 
A83V Valine 0 Small Hydrophobic 
 




A83M Methionine 0 Large Hydrophobic 
 
A83E Glutamic Acid 0 Acidic 
 
A83K Lysine 0 Basic 
 
Table 3. The viruses designed with mutations at position 83  
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RESULTS: 
Rescue of recombinant influenza viruses encoding M2-A83 mutations. 
Recombinant viruses expressing the panel of M2-A86 mutations shown in 
Table 2 were successfully rescued. The entire coding region of the M-segment 
from each virus was sequenced to confirm the presence of the desired 
mutation and to verify that no other amino acid changes were present.  
Plaque assay of A/Udorn/72 viruses containing M2-A83 mutations. As 
a first measure to determine if mutations at M2-A83 could alter influenza A 
virus replication, we determined the plaque morphology and size on MDCK 
cells. All of the viruses are able to form discernible plaques(Fig. 11A).The area 
of individual plaques was then calculated and viruses containing the 
M2-A83E and M2-A83K mutations generated slightly larger plaques 
compared to WT virus. This result indicates that the glutamine and lysine 
mutations, neither of which appears in natural isolates of influenza A virus, 
enhance influenza A virus plaque formation, though the effect is rather small.    
Replication of recombinant viruses encoding M2-A83 mutations at 
32°C. To characterize the replication of recombinant influenza A viruses 
encoding M2-A83 mutations, a multiple-step growth curve was performed on 
MDCK and differentiated hNEC cultures. To mimic the natural infection 
temperature of the upper respiratory tract, the growth curves were performed 
at 32°C. All the recombinant viruses reached peak virus titers at 72 hpi, but 
viruses encoding M2-A83E had slightly faster kinetics compared to WT virus 
  47 
at early times post infection in MDCK cells, though the differences were 
always less than 10-fold(Fig.12A). These data demonstrates that in MDCK 
cells under 32°C, M2-A83 mutation has little influence to virus replication. 
In hNEC cultures, recombinant viruses encoding M2-A83V, A83E and 
A83K showed slightly increased kinetics of virus production but had identical 
peak virus titers when compared to WT virus(Fig.13A). Interestingly, the virus 
encoding M2-A83M was severely attenuated in its replication, showing up to 
1000 fold less infectious virus production over multiple timepoints compared 
to WT virus. This hNEC growth curve demonstrated M2-A83 mutations have 
different effects on virus replication, depending on the amino acid substitution 
made.  
 






Figure. 11.  Effect of amino acid substitutions at position 83 of the M2 protein on 
influenza A virus plaque morphology in MDCK cells.Plaque morphology of 
recombinant influenza A viruses encoding mutations at position 83 of the M2 
protein.(B) Plaque area was calculated and mean(cross), median(line), 50% 
percentiles(box) and range(whiskers) are shown. Significant differences were 
determined by student t-test: * P≤0.05. At least 35 plaques were quantified for 
each virus.  





Figure. 12. Effect of amino acid substitutions at position 83 of the M2 protein on 
influenza A virus replication in MDCK cells at 32°C.(A) A multistep growth curve 
was performed on MDCK cells with the indicated recombinant viruses. In(B), 
representative viruses from(A) are shown. Statistical differences determined by 
MANOVA followed by Bonferroni post test: *=P<0.05; L.O.D=limit of 
detection=2.37. 
 








Figure. 13. Effect of amino acid substitutions at position 83 of the M2 protein on 
influenza A virus replication in hNEC cultures at 32°C(A) A multistep growth 
curve was performed on hNEC cultures with the indicated recombinant viruses. 
In(B), representative viruses from(A) are shown. Statistical differences determined 
by MANOVA followed by Bonferroni post test: *=P<0.05. **=P<0.01. ***=P<0.001. 
****=P<0.0001. L.O.D=limit of detection=2.37 
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DISCUSSION 
The cytoplasmic tail of the influenza A virus M2 protein contains 54 amino 
acids located at positions 44 to 97 of the protein(65). Besides the ion channel 
function which is important for virus entry, the M2 protein plays a role in the 
assembly of infectious virus particles(66). Various M2 protein truncations 
demonstrate the importance of amino acid sequences between positions 82 to 
90. Disruption of these protein sequences led to a defect in virus replication. 
This thesis was focused on M2 amino acids 83 and 86, which were not 
mutated previously and could be important determinants of efficient virus 
replication(53). In our study, we attempted to examine the role of two specific 
amino acid position M2-A83 and M2-A86 in virus replication by characterizing 
their mutations in plaque assays and multiple-step growth curves. Our 
characterization experiments demonatrate that M2-A83 and A86 positions 
play roles in A/Udorn influenza virus replication. Mutations at these 2 
positions can alter the replication kinetics and amount of infectious virus 
produced. Based on prior research on A/Udorn viruses with M2 protein 
truncations at position 70(M2stop70), M2 protein amino acid positions 70 to 
90 are not important for M2 protein incorporation into progeny virus particles 
but M2stop70 viruses have reduced virus infectivity, decreased NP 
incorporation, and reduced viral RNA incorporation into progeny virus 
particles. This reduction can be restored by the expression of full-length M2 
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protein in trans(61). Although M2 cytoplasmic tail amino acid position 71 and 
76 have been proved to be critical for virus replication(62), they may not be the 
only positions that are important because truncation at amino acid 82 also 
attenuates virus replication. Since both M2-A83 and M2-A86 position are 
located within the sequence 82-90, they may be part of a second region of the 
M2 cytoplasmic tail that is important in infectious virus production. To 
further investigate the role of mutations at positions 83 and 86 of the M2 
protein, high MOI infections should be performed and the amount of viral NP 
and viral RNA packaged into progeny virus particles determined. I would 
predict that mutations that attenuate virus replication would reduce NP and 
viral RNA incorporation while mutations that improve virus replication should 
increase NP and viral RNA incorporation.   
The structure of the M2 protein cytoplasmic tail from amino acids 72-97 
has not been solved. According to the Chou and Fasman algorithm, amino 
acid positions 82 to 87 form an alpha-helix secondary protein structure(55,56). 
In analyzing our data on virus replication and the predicted secondary 
structure changes of different mutated amino acids, it is difficult to find any 
consistency between the two: In M2-A83, V and K promotes replication while 
M drastically inhibits progeny virus production. Although introducing V and K 
to M2-A83 position makes that 82-87 alpha-helix disrupted by 1-2 amino 
acids, introducing M does not make any structural difference. A similar 
situation occurs with the M2-A86 mutations. Based on the Chou and Fasman 
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prediction(55,56), S, E and K may cause similar structural changes in the 
82-87 region, but my data shows only S and E but not K reduce the virus 
replication. These suggests that the alteration of virus replication may not be 
related to the Chou and Fasman predicted M2 cytoplasmic tail secondary 
structures, however, this awaits the determination of the actual M2 
cytoplasmic tail structure.  
The M2-A83 position has nearly 100% alanine for all human influenza A 
strains. M2-A86 position has alanine for most of human influenza A virus 
non-pandemic H1N1 strains(pH1N1), while M2-A86 has valine for the 
majority of pH1N1(54). Our data generated from growth curve suggests valine 
at A86 position has some inhibiting influence for virus replication of the H3N2 
influenza A virus A/Udorn(Fig.9), but not as much as serine and glutamic acid. 
It will be interesting to investigate the role of position 86 in pH1N1 viruses and 
perhaps confirm that the M2-A86V substitution contributes to that viruses 
ability to replicate efficiently.  
For both position 83 and 86, we generated panels of mutated virus based 
on introducing amino acids with different side chain characteristics. At 
position 86, LAIV strain mutation S and the basic amino acid E attenuate 
virus, which indicates that both hydrophobicity and polarity features of amino 
acid residues are factors responsible for the functions. This is also applicable 
to position 83, where the size of the hydrophobic side chain or the presence of 
the S-methyl thioether side chain cause mutation A83M to significantly 
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attenuate virus replication. To further study how the amino acid residue 
properties contribute to virus replication at each position, some additional 
mutations can be introduced into these positions. For example, an 
A86D(aspartic acid) mutation can be created and compared with A86E to 
determine the role of acidic side chains at this position.  
Our mutations are generated based on A/Udorn/307/72(H3N2) virus 
backbone, which is a widely used laboratory research strain(67) and also used 
in the prior studies on the effect of truncating the M2 cytoplasmic tail(53). 
Therefore, our results are the outcome of mutations interacting with A/Udorn 
backbone genes. For the A86S mutation in particular, it will be especially 
important to study its effects in the LAIV genetic background to determine if 
that position contributes to LAIV attenuation. If this reverse mutation can 
weaken the attenuation phenotype, which means the containing virus would 
replicate better than normal LAIV strain, then position 86 can be determined 
to be an attenuation-related position of the M2 protein. 
We used two types of cells in our studies: MDCK cells and hNEC cultures. 
Although MDCK cells are a widely used laboratory cell line to grow influenza 
virus and are easier and cheaper to use(68), they may not be the most relevant 
cell line for characterizing some aspects of influenza virus replication. Our 
results demonstrate the difference of using MDCK cells compared to hNEC 
cultures and - perhaps obviously - the more physiologically relevant hNECs 
are a better cell model to use for influenza research, especially for human 
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vaccine related experiments. MDCK cells are not able to show the variation of 
mutated strains we generated but hNECs can. This difference revealed by 
hNEC but not MDCK, is that specific mutations at position 86 resulted in 
viruses that replicated less effectively at 37°C than 32°C in hNEC, suggests 
that 86 position is related with a temperature sensitive phenotype that 
penetrates only on hNEC cultures(Fig.7A & Fig.9). Previous work focusing on 
the ts phenotype of cold adapted LAIV virus concluded that segments related 
to the ts phenotype are PB1, PB2 and NP, which carry 5 amino acid changes 
when LAIV is compared to its parental virus(63). However, their experiments 
are all based on MDCK cells. We discovered an additional ts phenotype from 
the M2-A86S mutations in hNECs, which suggests hNECs are a better cell 
culture model for influenza virus research. Of course, hNEC cultures are 
difficult to obtain and maintain so they are certainly not as convenient as 
MDCK cells. The choices of these two cells would be important for further 
influenza virus research. 
Our research extends our understanding of influenza A virus replication 
and provides additional amino acid positions that can alter virus replication. 
This could be important information used for designing improved influenza 
LAIV vaccines. The current live-attenuated influenza vaccine are only 
approved for individuals between 2 to 49 years of age(69). However, these two 
groups of people indeed have higher needs of immunological protection than 
others due to their weaker immune responses(70). They urgently need a safer 
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live-attenuated vaccine for protection, and we may generate more attenuated 
influenza A virus strain to fit this need based on the points we found.  
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FUTURE DIRECTION 
Our study identified specific mutations at two positions in the M2 protein 
that altered virus replication kinetics and infectious virus production. 
However, we still lack detailed knowledge about the core mechanisms 
responsible for these differences. Based on prior studies(61), we assume that 
this mechanism is that M2-A83 and M2-A86 positions are important for 
progeny virion genome packaging. To verify this assumption, it is necessary to 
measure the RNA amount of progeny virus of mutated viruses. 
Also, as we demonstrate the attenuation of M2-A86S strain virus, 
characterizing similar mutations in the LAIV strain backbone would be 
informative. The contribution of M2 86 amino acids to LAIV attenuation need 
to be determined to see if the degree of attenuation is comparable to that seen 
with A/Udorn A86S virus.  
We also poorly understand the impact of mutated virus infection to host 
immune response. Since we use hNECs to research, measuring the innate 
immune factors(interferon, chemokines and cytokines) produced post 
infection could be a reasonable point to start. 
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